A life-sciences focused venture capital firm currently making investments into US-based companies out of its fourth fund primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment. The firm could make as many as 3 new investments over the next 6-9 months.
The firm is looking for U.S. companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and digital health. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement.
The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm Invests in Seed and Early Venture Rounds, Investing Broadly Across All Life Science Sectors and Focusing on USA-Based Opportunities
8 DecHot Investor Mandate: Impact Investment Evergreen Fund Actively Invests in All Life Science Technologies Relevant to Oncology Indications
8 DecAn impact investment arm of a non-profit organization manages an evergreen fund and is interested in therapeutics, diagnostics or screening technology, medical devices, digital health or tech enabled services that align with the firm’s mission to advance the fight against cancer. The firm will invest in companies of all stages of development (excluding public companies), and looks for companies that are advancing science, reducing disparities, and promoting health care sustainability; though there is a preference for Seed and Series A stage companies. The firm’s typical check size ranges from $250K-$2 million per round and reserves additional funds for follow-on investments. The firm is currently looking to co-invest, and will consider global opportunities, but is currently investing mostly in the US.
While relatively agnostic to technology within therapeutics, medical devices, diagnostics and digital health, The firm will only invest in companies relevant to the indication of oncology.
The firm is looking to co-invest in private companies only.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based VC Invests In Software-Based, Data-Driven Life Science and Healthcare Technologies With a Focus on North America Companies
8 DecA USA-based firm is investing from its second fund and manages about $150M AUM. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.
The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.
The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Bridging the Gap between Academia and Industry
6 DecBy Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Mansfield Bio-Incubator Chief Operating Officer, Alexander Margulis has been in the Life Sciences industry for over 20 years and is passionate about creating a robust and accessible entrepreneurial community among local universities, startups, and investors. Less than 1-hour away from Boston and Cambridge, the facility provides affordable private and shared spaces for research labs, mentorship and networking opportunities. In addition, they offer several resources such as access to professional advisors and assistance with government and private funding research applications. Currently, Mansfield Bio-Incubator hosts over 20 early-stage startups ranging from therapeutics, medical devices, and cleantech in the life sciences areas of oncology, women’s health, animal health, biomaterials, water purification, and more.
Listen to our conversation to learn more about how Alexander and his team are creating, growing, and ensuring the success of the next generation of life science companies at Mansfield Bio-Incubator.
Vessl Prosthetics at RESI
1 DecBy Rikki Piccirillo, Marketing Manager, LSN
Co-Founders, Sydney Robinson and Oleksiy Zaika of Vessl Prosthetics joined us at RESI Boston in September. With an understanding of the value of building relationships early in their fundraising journey, attending RESI made perfect sense. This team made the most of their time at RESI, researching attending investors, strategizing panel attendance, and capitalizing on every learning and networking opportunity that presented itself. As thorough and prepared as they were for their time at RESI, the same zest can be said for how Vessl Prosthetics came to be. In this interview with Sydney, you can learn more about their company, the product their developing and their strategy at RESI:
Registration is open for RESI JPM San Francisco, January 10 In Person at the Marines’ Memorial Club & Hotel & January 11-12 online Virtual Partnering.
RESI JPM San Francisco Sponsor Highlight – Husch Blackwell
1 DecBy Antoinette Lowre, Manager of Business Development, LSN
Life Science Nation was thrilled to have Hush Blackwell at RESI Boston in September as a Silver Sponsor. Their sponsorship included a workshop, Leveraging IP for Growing an Investable Medtech Company, hosted by Hush Blackwell Partner, Bryan Stewart. This panel highlighted the importance of IP leverage and included testimonials and insight from some of their current clients. Bryan stated:
“The Husch Blackwell team had a great experience sponsoring the RESI Boston conference. We featured founders from funded companies restor3d, Trio Labs, and protect3d on our panel presentation titled ‘Leveraging IP for Growing an Investable MedTech Company.’ Our team and our panelists enjoyed the industry-relevant RESI presentations, the pitch competitions, and networking with others in the RESI and LSN ecosystem. We found sponsoring RESI Boston immensely valuable – we will be back sponsoring RESI JPM!”
Husch Blackwell will be at RESI JPM in San Francisco as a Gold Sponsor and will be hosting another panel during our packed 1-day in person event on January 10, followed by two virtual partnering days.
To learn more about sponsorship and the benefits of sponsoring at RESI JPM, check out our Sponsorship Brochure and reach out to RESI@lifesciencenation.com with any questions or to book a meeting with your business development rep.
Join Us as a Media Partner in 2023
1 DecBy Caitlin Dolegowski, Marketing Manager, LSN
Calling all life science industry media producers: partner with us in promoting Life Science Nation (LSN)’s RESI conference series in 2023, and get valuable discounts for the members of your ecosystem!
LSN’s partnering conference series is the biggest in North America focusing on early-stage life science investments and strategic partnerships. At each conference event, we expect between 700-1,200 attendees participating from 5 continents.
Media partnership isn’t just a promotional tool for publicity and customer loyalty, it can also be expected to generate good will and awareness at LSN’s conference series. LSN makes media sponsorship as convenient as possible. As a media sponsor, you would promote and advertise LSN partnering conferences through your communication channels, and in return, LSN offers including:
- Your logo on LSN’s Next Phase Newsletter (45,000+ readership), event websites, and program guide.
- A unique discount for your subscribers for RESI conferences.
- Our media partners receive a complimentary ticket and additional free tickets for every two registrations you provide.
For additional exposure we offer two posts of our LinkedIn network and a banner ad featured in our newsletter during 2023.
For more information, please contact Caitlin Dolegowski, Marketing Manager, LSN
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 